Andy Murray
CEO
Sania Therapeutics
Sania Therapeutics is developing precision gene therapies that utilize targeted delivery systems to treat prevalent nervous system disorders. Their approach aims to enhance therapeutic control and efficacy, addressing the unmet medical needs in this underserved area.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$11.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many nervous system disorders lack effective treatments due to the challenges of delivering therapeutics precisely to the affected areas without causing widespread side effects. Current treatment options often fail to address the underlying causes of these disorders, leaving a significant unmet medical need.
Solution
Sania Therapeutics is developing precision gene therapies that leverage targeted delivery systems to treat prevalent nervous system disorders. Their approach focuses on enhancing therapeutic control and efficacy by utilizing the nervous system as an access point. By combining targeted delivery mechanisms with controllable therapeutics, Sania aims to redefine the treatment landscape for these underserved disease areas, offering more precise and effective interventions.
Target Audience
Sania Therapeutics targets individuals suffering from prevalent nervous system disorders and the healthcare providers who treat them.
Features
- Targeted delivery systems for precise therapeutic administration within the nervous system.
- Controllable therapeutic mechanisms to modulate treatment intensity and duration.
- Focus on prevalent and underserved nervous system disorders.
- Development of gene therapies to address the underlying causes of disease.